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Alzheimer’s disease based on structural MRI
Lene Lillemark1*, Lauge Sørensen1, Akshay Pai1, Erik B Dam2, Mads Nielsen1,2 and Alzheimer’s Disease
Neuroimaging Initiative
Abstract
Background: Alzheimer’s disease (AD) is a progressive, incurable neurodegenerative disease and the most common
type of dementia. It cannot be prevented, cured or drastically slowed, even though AD research has increased in the
past 5-10 years. Instead of focusing on the brain volume or on the single brain structures like hippocampus, this paper
investigates the relationship and proximity between regions in the brain and uses this information as a novel way of
classifying normal control (NC), mild cognitive impaired (MCI), and AD subjects.
Methods: A longitudinal cohort of 528 subjects (170 NC, 240 MCI, and 114 AD) from ADNI at baseline and month 12
was studied. We investigated a marker based on Procrustes aligned center of masses and the percentile surface
connectivity between regions. These markers were classified using a linear discriminant analysis in a cross validation
setting and compared to whole brain and hippocampus volume.
Results: We found that both our markers was able to significantly classify the subjects. The surface connectivity
marker showed the best results with an area under the curve (AUC) at 0.877 (p < 0.001), 0.784 (p < 0.001), 0,766
(p < 0.001) for NC-AD, NC-MCI, and MCI-AD, respectively, for the functional regions in the brain. The surface
connectivity marker was able to classify MCI-converters with an AUC of 0.599 (p < 0.05) for the 1-year period.
Conclusion: Our results show that our relative proximity markers include more information than whole brain and
hippocampus volume. Our results demonstrate that our proximity markers have the potential to assist in early
diagnosis of AD.
Keywords: Alzheimer’s disease, Mild cognitive impairment, Bio markers, MRI, Diagnosis and classification, Proximity
Background
Alzheimer’s Disease (AD) is the sixth-leading cause of
death in the US and accounts for 50-56% of the cases of
diagnosed dementia [1]. AD is often diagnosed in people
over 65 years but the onset for AD can occur much earlier.
The population of aged 65+ years in the US is estimated to
double by the year 2030 [1]. This means that the number
of new and existing cases of AD will increase drastically
as well. At the moment, no cure or treatment is found for
AD which obviously makes it a growing problem [1].
The causes of AD are not fully clarified. Research
indicates that accumulation of twisted protein fragments
inside the nerve cells, neurofibrillary tangles, and toxic
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protein fragment, amyloid beta oligomers, are character-
istics of AD [2,3]. The hippocampus, which is associated
with memory, is particular vulnerable to damage at the
earliest stages of AD [3,4]. Hippocampal brain changes,
such as loss of thickness and volume in the medial tem-
poral lobe, particular in the hippocampus, is thought to
begin 7 years or more before AD symptoms, such as
memory loss, appear [5-8].
The cognitive decline can be slowed when administered
during the early stage of disease [9], and therefore early
detection of brain changes is highly desirable, both to
increase the quality of AD patient’s life but also for future
developments in drug trials.
Structural magnetic resonance imaging (MRI) has
shown great applicability to map how AD spreads in the
living brain. Recent literature have studied the accuracy
and reproducibility of MRI-derived measurements and
© 2014 Lillemark et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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found correlation with clinical measurements and positive
prediction of future decline [10-12]. MRI is non invasive
and is largely available in the clinical environment, and
has therefore become a viable tool to monitor the progres-
sion of AD. Longitudinal measurement changes may be
more objective, precise, and reproducible when they are
measured from MRI compared to diagnostic image mea-
surements from PET scanning or CSF measurement of
amyloid and tau protein.
Different studies have focused on the hippocampus
region and used atrophy scoring and shape analysis for
detection of AD [13-16]. Also whole brain atrophy scor-
ing have been extensively used for detection of AD [17,18].
The same techniques have been used to classify MCI-
converters (MCI-c) from MCI-non-converters (MCI-nc),
indicating that it is possible to make a prognosis of AD
based on atrophy rates, shape analysis, region hippocam-
pal shapes and machine learning techniques [10,19-24].
The general focus on studies from MRI have been on
the atrophy rates for hippocampus or the whole brain,
or the shape of hippocampus, but other brain structures,
like amygdala, putamen, thalamus, and the ventricles have
also shown relation to AD [25-27]. We want to include
all of these structures in order to investigated the rela-
tionship and proximity between different regions in brain
in hope to characterize how the brain develops and use
this as a marker for AD. We believe that the relationship
between the positions of different regions or the surface
connectivity between the different regions in the brain can
capture how the atrophy spreads. We have used a Pro-
crustes marker that classified AD subjects based on the
position of the center of mass of each region in a Pro-
crustes aligned environment, and a surface connectivity
marker that extracted the percentile surface connectivity
between the individual regions. The Procrustes marker
can capture how the regions move away or toward each
other indicating how the volume loss is different across
the brain. The surface connectivity marker can describe
the individual volume loss of the regions and how they
move apart due to for example the increase in ventricles
and cerebrospinal fluid (CSF). These new markers could
give a more detailed view of the AD progression and may
be used in addition to the traditional morphometric mark-
ers. Our markers were used in three different groupings
of the brain regions; a group of all Freesurfer segmented
regions, a subset of the functional regions, and a subset of
the small potato shaped regions (for example hippocam-
pus and amygdala) to classify, using a linear discriminant
analysis, NC, MCI, and AD. This was done in compari-
son to the whole brain volume and hippocampus volume.
Potentially, this could lead to a fine-to-coarse scale from
where one can study the progression of AD from the
global brain scale down to the local scale of the shape
and/or texture of the individual sub-regions.
Methods
ADNI brain MRI and preprocessing
Data was obtained from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) database (adni.loni.usc.
edu) [28]. The ADNIwas launched in 2003 by theNational
Institute for Aging (NIA), the National Institute of Bio-
chemical Imaging and Bioengineering (NIBIB), the Food
and Drug Administration (FDA), private pharmaceutical
companies and non-profit organizations as a $ 60 mil-
lion, 5-year public-private partnership. The primary goal
of ADNI has been to test whether serial MRI, positron
emission tomography PET, other biological markers, and
clinical and neurophysiological assessments can be com-
bined to measure the progression of MCI, and early AD.
Determination of sensitive and specific markers of very
early AD progression is intended to aid researchers and
clinicians to develop new treatments and monitor their
effectiveness, as well as lessen the time and cost of clin-
ical trials. The Principal Investigator of this initiative is
Michael W. Weiner, MD, VA Medical Center and Uni-
versity of California - San Francisco. ADNI is the result
of efforts of many co-investigators from a broad range of
academic institutions and private corporations, and sub-
jects have been recruited from over 50 sites across the U.S.
and Canada. The initial goal of ADNI was to recruit 800
subjects but ADNI has been followed by ADNI-GO and
ADNI-2. To date these three protocols have recruited over
1500 adults, ages 55 to 90, to participate in the research,
consisting of cognitively normal older individuals, people
with early or late MCI, and people with early AD. The fol-
low up duration of each group is specified in the protocols
for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally
recruited for ADNI-1 and ADNI-GO had the option to
be followed in ADNI-2. For up-to-date information, see
www.adni-info.org.
Longitudinal brain T1 weighted MRI and associated
data for the study population including age, gender, and
diagnosis were downloaded from the ADNI database. All
data in this paper were from ADNI-1. ADNI-1 was a
five year study launched in 2004 to develop longitudi-
nal outcome measures of Alzheimer’s progression using
serial MRI, PET, biochemical changes in CSF, blood and
urine, and cognitive and neuropsychological assessment
acquired at multiple sites similar to typical clinical tri-
als. All subjects underwent clinical and cognitive assess-
ment at the time of scan acquisition. All AD subjects
met NINCDS/ADRDA criteria for probable AD [29]. The
study was conducted according to the Good Clinical Prac-
tice guidelines, the Declaration of Helsinki and U.S. 21
CFR Part-50 Protection of Human Subject, and Part 56-
Institutional Review Boards. This study was approved by
the Institutional Review Boards of all of the participating
institutions and informed written consent was obtained
from all participants at each site.
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MRI acquisition
High-Resolution structural brain MRI were acquired at
59 ADNI sites using 1.5 Tesla T1-weighted MRI scans
using volumetric 3D MPRAGE or equivalent protocols
with varying resolution; typically 1.25 × 1.25 mm in-
plane spatial resolution and 1.2 mm thick sagital slices.
The MPRAGE sequence was acquired twice for all sub-
jects at each visit to improve the chance that at least one
scan would be suitable for analysis. The image quality was
graded qualitatively by ADNI investigators of the ADNI
MRQ quality control center at the Mayo Clinic for arti-
facts and general image quality. Each scan was graded on
several separate criteria: blurring/ghosting, flow artifacts,
intensity a homogeneity, signal-to-noise ratio, susceptibil-
ity artifacts and gray-white/cerebrospinal fluid contrast.
We have only used the MRI scan which was graded as
the best scan for each subject. No other exclusion crite-
ria based on image quality were applied. We have used the
raw ADNI data.
Participants
The criteria for inclusion were those defined in the
ADNI protocol; normal control (NC) subjects had a
mini mental state examamination score (MMSE) between
24 - 30, a clinical dementia rating (CDR) score of zero,
they were non-depressed, non MCI, and non-demented.
MCI had MMSE scores between 24-30, a memory com-
plaint, had objective memory loss measured by education
adjusted scores onWechsler Memory Scale Logical Mem-
ory II [30], a CDR of 0.5, absence of significant lev-
els of impairment in other cognitive domains. AD sub-
jects had MMSE scores between 20-26, CDR of 0.5
or 1.0 and met NINCDS/ADRDA criteria for proba-
ble AD. We selected a subset of 528 participants in
the ADNI study. We have chosen a training set of
101 subjects based on statistics and visual inspection
in order to get representative data which also included
the difficult images, e.g., with image noise, and huge
deformation to allow validation of our methods on a
hard data set, which makes significant results more
plausible.
The remaining 427 were taken as ADNI-1 data set [31]
minus the overlap with the 101 subjects selected for train-
ing. Our subset population included 174 NC (age at base-
line (bl) 76.0 years (y) ±5.1 y , 89 males (M)/85 females
(F), 240 MCI (age at bl 74,9 y±7.0y, 159M/81F), and 114
AD subjects (age at bl 74 y ±7.3 y, 58M/56F). There
was 4 NC, 21 MCI and 7 AD subjects in our study that
was under 65 y. Even though there is evidence that the
pathology is different in early-onset AD and late-onset AD
we have included the subjects under 65 because they do
not have verified early onset AD [32]. The demographic
details of our training and testing subjects are shown in
Table 1.
Freesurfer segmentation
The segmentation of the regions was performed by static
FreeSurfer [33] implemented on a Linux cluster with 24
cores with 18 GB RAM per CPU. Freesurfer is a set of
software tools designed to study the cortical and sub-
cortical anatomy of the brain. Freesurfer do an affine
registration of the volumes with the Talairach atlas [34],
a non-uniform intensity normalization (N3) [35] and a
B1 bias field correction [36]. A skull stripping step was
performed using a deformable template model. Voxels
were then defined as white matter or not white matter
based on intensities. Hereafter, cutting planes were used
to separate the hemispheres, cerebellum and brain stem.
A cortical and subcortical labeling was performed based
on a transformation that maps the individual subjects into
a probabilistic atlas. The atlas was build based on a train-
ing set where the subjects have been labeled by hand and
currently consists of 39 subjects distributed in age and AD
pathology (28 NC and 11 with questionable or probable
AD) [37]. The classification of each point was achieved by
finding the segmentation that maximized the probability
of input given the prior probability from the training set
in a iteratively manner.
Grouping of the segmented regions
The FreeSurfer segmentation provided 40 regions from
which a visualization is shown in Figure 1. AD do not
spread evenly across the brain and we are interested in
capturing early signs of AD and the conversion fromMCI
to AD [3,25]. Therefore have we divided our regions into
three groups; all, functional (func) and potato, described
in Table 2. These groups are spread across the brain so
we are not biasing toward anatomical placed groupings.
The all group included the FreeSurfer segmented regions
excluding left-vessel, right vessel and 5th ventricle because
these regions were not segmented by FreeSurfer in all sub-
jects. The functional group has excluded all non-function
regions like CSF and hypointensities. The choroid plexus
was included in the functional regions due to suggestions
that the functionality is altered in the choroid plexus due
to AD [38]. To get a even smaller subset, the potato group
consisted of small potato shaped regions from a visual
perspective where shape is clearly defined.
Surface connectivity marker, procrustes marker, and
volumemarker
We assume that proximity may reflect aspects of func-
tional brain connectivity and have therefore looked at
both the individual regions positional relationship, and
how they relate to each other. We have calculated the
percentage of how much of a regions own surface was
connected to the surface of all other regions resulting
in a surface connectivity marker. This was done non-
symmetric in a voxel-count based manner on the three
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Table 1 The demographic details of our study population
Group Number Age at bl (years) Gender (M/F) MMSE at bl
NC training set 24 75.3 ± 4.4 [65.1 − 85.9] 14 M/10 F 29.3 ± 1.1 [26 − 30]
MCI training set 29 73.6 ± 7.3 [55.2 − 85.5] 19 M/10 F 27.2 ± 1.6 [24 − 30]
AD training set 48 74.8 ± 6.7 [62.5 − 87.9] 24 M/24 F 23.5 ± 1.9 [21 − 26]
NC 174 76.0 ± 5.1 [60.0 − 89.7] 89 M/85 F 29.2 ± 1.0 [25 − 30]
MCI 240 74,9 ± 7.0 [55.2 − 88.4] 159 M/81 F 27.1 ± 1.7 [24 − 30]
AD 114 74,7 ± 7.3 [56.5 − 89.2] 58 M/56 F 23.3 ± 1.9 [20 − 26]
MMSE = mini mental state examination score. Values are indicated as mean ± standard deviation [range]. There is 4 NC, 21 MCI and 7 AD subjects in our study that is
under 65.
dimensional data so we had a unique image of each region
where zero means that there was no connections between
the regions and an increasing percentage number referred
to how much surface connectivity existed. This way we
could observe if shrinkage of regions relates to more fluid
in between regions or general shrinkage where the relative
sizes did not change.
The individual regions and their internally relationship
was investigated as a change in position of the individual
region. We calculated the center of mass c ∈ R for each
region P as the mean position of all the points inside the
regions in all of the coordinate directions:
c · ed = 12V
N−1∑
i=0
∫
Ai
(x · ed)2(ni · ed), d =1,2,3 (1)
where ed denote the standard basis in R by {e1, e2, e3} and
V denote the volume. These points were aligned with a
Procrustes alignment, where they were adjusted to be in
Figure 1 A slide of the segmented brain where the segmented
regions have different colors.
the same space by translation, rotation and scaling of the
points [39]. We used the mean shape as the starting shape.
This resulted in a feature vector in a machine learning set-
ting that was able to describe the variations in the points
related to the disease status.
For comparison we have used the volume measurement
for the whole brain and for hippocampus, for which good
classification results earlier have been reported [18,19,40].
The whole brain volume fraction included all regions in
the skull-stripped brain except for vessels and CSF divided
with the intracranial volume. The hippocampus volume
fraction was also measured as the lateral hippocampus
volume divided with the intracranial volume. A summary
of our markers is shown in Table 3.
Dimensionality reduction and classification
We wanted to reduce the number of parameters in the
case of Procrustes and surface connectivity due to the
curse of dimensionality where we had more parame-
ters than observations. We wanted to maintain the rela-
tionship between the predictive and target parameters
and have therefore chosen to do dimensionality reduc-
tion using partial least square regression (PLS) [41]. The
idea behind PLS is to find the relevant variables X that
Table 2 The three different groups of the regions; all,
functional and potato and the regions belonging to each
group
All CSF, 3rd-Ventricle, 4th-Ventricle, Brain-Stem, Optic-Chiasm
WM-hypointensities, non-WM-hypointensities, left and right
cerebral white matter, cerebral cortex, lateral ventricle, inf
lateral ventricle, cerebellum white matter, cerebellum cortex,
thalamus, caudate, putamen, pallidum, hippocampus,
amygdala, accumbens area, ventralDC, choroid-plexus
Func Left and right cerebral white matter, cerebral cortex, inf
lateral ventricle, cerebellum white matter, cerebellum cortex,
thalamus, caudate, putamen, pallidum, hippocampus,
amygdala, accumbens area, choroid-plexus
Potato Left and right lateral ventricle, cerebral
white matter, thalamus, caudate, putamen, pallidum,
hippocampus, amygdala
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Table 3 An overview of the names and description of the
markers we used in this paper
Marker Description
Procrustes The center of mass of each regions aligned
to the same space with a Procrustes alignment.
Surface connectivity The percentage of how much each region
have connected to other regions related
to the surface of the region.
Hippocampus volume The volume of the hippocampus divided
with the intracranial volume.
Whole brain volume The volume of the whole brain divided
with the intracranial volume.
accounts for as much information of the data Y as pos-
sible. PLS searches for the set of components (latent
variables) that performs a simulation decomposition of X
and Y with the constraint that these components should
explain as much as possible of the covariance between
X and Y . It is followed by a linear regression step where
the decomposition of X is used to predict Y . The PLS
model will try to find the multidimensionality direction in
the X space that explains the maximummultidimensional
variance direction in the Y space. The number of PLS
components were set to 10 based on our training experi-
ments. Due to its simple functionality we have used linear
discriminate analysis (LDA) for the classification [42].
LDA tries to reduce the dimensionality while preserving
as much of the class discriminatory information as pos-
sible. LDA seeks to obtain a scalar y by projecting the
samples x onto a line y = wTx where x is the samples
and w contains the class information. Of all possible ways
to discriminate these we would like to select the one that
maximizes the separability between the scalars y.
All experiments were done in a leave-one-of-each-
class out fashion. The data were adjusted for age and
gender when there existed a linear correlation between
those.
Result
The fractional volume scores for the whole brain volume
and hippocampus volume for NC, MCI, and AD, respec-
tively is shown in Table 4. NC had a larger volume in
both whole brain and hippocampus than MCI and AD,
and MCI had a larger volume score than AD. AD had the
largest volume lost between bl and m12.
For each feature set the area under the curve (AUC) was
computed and summarized in Table 5 for NC versus AD,
NC versus MCI, and MCI versus AD and the correspond-
ing ROC curves are shown in Figure 2. The classification
was tested with a ranksum test and the p-values are also
shown in Table 5. All markers were able to significantly
discriminate between the three groups NC-AD, NC-MCI,
and MCI-AD. The AUC score were highest for the NC-
AD group, where our surface connectivity marker were
comparable to the hippocampus volume for the AD-NC
and NC-MCI cases and better in the discrimination for
the MCI-AD case than the hippocampus volume. The
AUC for the Procrustes marker were in general a little
lower than for the surface connectivity score.
Next, we adjusted our markers for whole brain volume
and for hippocampus volume to investigate if our mark-
ers contained additional information than the volumes.
These results are shown in Table 5. The signal lowers
but was still significant. Again, the surface connectivity
markers performed better then the Procrustes markers
and the NC-AD classification result were the best. The
surface connectivity markers were generally better to dis-
criminate NC-MCI than MCI-AD, and for the Procrustes
markers it was vice versa. It was the smaller group-
ings; functional and potato-shaped, that gave the best
performance.
We have also investigated how our markers performed
on the period to month 12 using the score differences
between bl and month 12 for each marker, and the AUC
and the corresponding ranksum p-values are shown in
Table 6 and roc curves in Figure 3. Hippocampus and
whole brain showed relatively low AUC result due to the
Table 4 Fractional volume scores for the hippocampus and the whole brain at bl andmonth 12, and the volume loss
Group Time point Whole brain Hippocampus
volume fraction (cm3) volume fraction (cm3)
NC bl 0.6139 (±0.0451) 0.0045 (±6.6958e-004)
n = 170 month 12 0.6087 (±0.0465) 0.0044 (±7.0889e-004)
delta 0.0050 (±0.0146) 9.7840e-005 (±3.1796e-004)
MCI bl 0.5908 (±0.0398) 0.0038 (±6.7920e-004)
n = 240 month12 0.5815 (±0.0422) 0.0037 (±6.8807e-004)
delta 0.0084 (±0.0155) 1.4248e-004 (±2.5027e-004)
AD bl 0.5769 (±0.0410) 0.0035 (±6.2344e-004)
n = 114 month12 0.5666 (±0.0402) 0.0033 (±5.9287e-004)
delta 0.0106 (±0.0136) 1.6425e-004 (±2.6376e-004 )
All scores were normalized by the intracranial volume. NC had the larges volume scores and AD had the largest volume loss.
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Table 5 The AUC values and corresponding ranksum p-values for classification of AD-NC, NC-MCI, andMCI-AD
(a) Baseline data, not adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
HP/ICV 0.878 < 0.001 0.783 < 0.001 0.635 < 0.001
WB/ICV 0.724 < 0.001 0.648 < 0.001 0.648 < 0.001
Surface all 0.818 < 0.001 0.765 < 0.001 0.740 < 0.001
Surface func 0.877 < 0.001 0.785 < 0.001 0.766 < 0.001
Surface potato 0.849 < 0.001 0.785 < 0.001 0.736 < 0.001
Procrustes all 0.769 < 0.001 0.679 < 0.001 0.707 < 0.001
Procrustes func 0.784 < 0.001 0.656 < 0.001 0.712 < 0.001
Procrustes potato 0.752 < 0.001 0.640 < 0.001 0.705 < 0.001
(b) Baseline whole brain, bl. volume adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
Surface all 0.752 < 0.001 0.664 < 0.001 0.574 0.024
Surface func 0.839 < 0.001 0.695 < 0.001 0.597 0.006
Surface potato 0.787 < 0.001 0.705 < 0.001 0.600 0.003
Procrustes all 0.678 < 0.001 0.566 0.001 0.520 0.022
Procrustes func 0.689 < 0.001 0.539 0.006 0.572 < 0.001
Procrustes potato 0.650 < 0.001 0.513 0.010 0.582 < 0.001
(c) Baseline hippocampus volume, bl. volume adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
Surf all 0.639 0.001 0.608 < 0.001 0.688 < 0.001
Surf nfunc 0.739 < 0.001 0.615 < 0.001 0.729 < 0.001
Surf potato 0.667 < 0.001 0.622 < 0.001 0.671 < 0.001
Procrustes all 0.624 0.001 0.575 0.010 0.663 < 0.001
Procrustes nfunc 0.631 < 0.001 0.553 0.068 0.671 < 0.001
Procrustes potato 0.574 0.041 0.529 0.328 0.658 < 0.001
The last two markers were divided in three groups all, functional, and potato-shaped. 5(a) is the non-adjusted case, 5(b) and 5(c) is adjusted by whole brain fraction
and hippocampus fraction, respectively. All markers were able to significantly distinguish the classes. Our markers were still significant after adjustment for the two
volume scores, but AUC scores were in general lower than the non-adjusted scores. The surface connectivity score for the functional groups performed the best.
use of static Freesurfer volumes from bl and month 12.
Our surface connectivity scores performed the best for all
three groups NC-AD, NC-MCI, andMCI-AD. The results
between NC-AD and NC-MCI are very similar.
We have adjusted the month 12 classification results for
both the baseline whole brain and the baseline hippocam-
pus volume shown in Table 6. The results showed a sig-
nificant classification for our markers. When adjusted for
whole brain volume the surface connectivity performed
the best. The classification result for MCI-AD case was
better than the NC-AD result.
Finally, we have classifiedMCI-c against MCI-nc, where
the non-adjusted result is shown in Table 7. The sur-
face connectivity markers was the only marker that was
able to distinguish the two groups and only in the func-
tional and potato-shaped grouping of regions. When we
adjusted for whole brain volume the surface connectiv-
ity marker was still significant with an AUC at 0.631
(p = 0.012) and for the potato group it was borderline
significant with an AUC at 0.595 (p = 0.067). In the
case where we adjusted for hippocampus volume, only
the surface connectivity marker for the functional groups
was borderline significant with an AUC of 0.599 (p =
0.055). No other significance were shown in the adjusted
cases.
Discussion and conclusion
We have investigated a novel way of looking at the rela-
tionship between different regions in the brain. We eval-
uated a surface connectivity marker and center of mass
based marker and their ability to classify between NC,
MCI, and AD subjects. Both markers have been able to
significantly discriminate between the three classes AD-
NC, NC-MCI, andMCI-AD both at baseline and between
baseline and month 12. Our surface connectivity marker
was also able to classify MCI-c.
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Figure 2 (a) show the ROC for AD vs NC, (b) shows the ROC for NC vs. MCI, and (c) shows the ROC for MCI vs. AD.
The large variability’s in the brain regions is related to
Alzheimer’s Disease [17,19,25-27], and this have moti-
vated our two markers describing the proximity between
the regions in the brain. Both our markers were able
to significantly differentiate between AD and NC, also
when adjusted for whole brain and hippocampus volume.
The surface connectivity marker was comparable to hip-
pocampus volume, which is one of known most effect full
markers from MRI. Also after adjustment for volumes we
had a significant classification results, this indicates that
our markers hold additional information about the devel-
opment of the brain in relation to progression of AD.
We believe that our markers capture an individual shrink-
age due to pathological alterations. In subjects with AD
the cerebral cortex is shrinking, the sulci’s is widened,
the cortical ribbon may be thinned and ventricles are
dilated [2,43,44]. Our surface connectivity markers may
capture some of these pathological alterations in measur-
ing the proximity between regions.
We have evaluated our markers over a 1 - year period
where we have investigated the change in the Procrustes
aligned positions and the change in surface connectivity.
In this case, we were also able to significantly discrim-
inate between the classes, although the signal was less
strong. The weakened signal can be due to noise in the
segmentation of the data. Our markers were not taken
from registered brains but normalized within the same
brain so they captured comparable information across
time and study population. The segmentation of the indi-
vidual regions at two time steps can still be quite differ-
ent and when we were using the difference between the
score values it can introduce noise in our markers. This
is also visible in the values for hippocampus and whole
brain volume in the longitudinal part of our study, which
showed lower results for classification than other reported
results [17,45].
Our surface connectivity marker performed the best
indicating that it captured how the cell death caused by
AD minimizes the surface connectivity between regions.
This was most visible in the functional regions. The func-
tional group were limited to functional regions of the
brain and the good performance of this grouping is in line
with the knowledge that AD affect the network around
and including the medial temporal lobe and disruption in
this region contributes to memory impairment [46]. The
lower performance of our Procrustes marker could be due
to the captured information is closer to volume and that
no particular regions moves related to the others, but all
regions moved due to general volume loss.
Cuingnet et al. [18] have made a comparison study
for classification of NC versus AD, NC versus MCI-
converters (MCI-c), and MCI-c versus MCI-non-
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Table 6 Classification result for NC-AD, NC-MCI, andMCI-AD for the difference between the bl andmonth 12makers 6(a)
is the not adjusted case, 6(b) is adjusted for bl whole brain volume and 6(c) is adjusted for baseline hippocampus volume
(a) Delta values, not adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
HP/ICV 0.579 0.068 0.567 0.030 0.526 0.030
WB/ICV 0.600 0.020 0.588 0.004 0.588 0.004
Surface all 0.664 < 0.001 0.643 < 0.001 0.719 < 0.001
Surface func 0.729 < 0.001 0.732 < 0.001 0.736 < 0.001
Surface potato 0.716 < 0.001 0.717 < 0.001 0.718 < 0.001
Procrustes all 0.630 < 0.001 0.591 0.002 0.672 < 0.001
Procrustes func 0.636 < 0.001 0.612 < 0.001 0.676 < 0.001
Procrustes potato 0.695 < 0.001 0.626 < 0.001 0.681 < 0.001
(b) Whole brain, bl. volume adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
Surface all 0.629 0.003 0.630 < 0.001 0.725 < 0.001
Surface func 0.657 0.000 0.704 < 0.001 0.739 < 0.001
Surface potato 0.645 0.001 0.681 < 0.001 0.707 < 0.001
Procrustes all 0.605 0.004 0.575 0.011 0.655 < 0.001
Procrustes func 0.593 0.011 0.586 0.003 0.647 < 0.001
Procrustes potato 0.640 0.000 0.600 0.001 0.657 < 0.001
(c) Hippocampus volume, bl. volume adjusted
NC-AD AUC p−value NC-MCI AUC p−value MCI-AD AUC p−value
Surface all 0.591 0.034 0.597 0.002 0.712 < 0.001
Surface func 0.575 0.082 0.649 < 0.001 0.704 < 0.001
Surface potato 0.582 0.056 0.630 < 0.001 0.681 < 0.001
Procrustes all 0.580 0.028 0.564 0.028 0.659 < 0.001
Procrustes func 0.583 0.022 0.573 0.013 0.657 < 0.001
Procrustes potato 0.615 0.002 0.577 0.008 0.664 < 0.001
Our markers was still able to significantly discriminate between the three groups. Our surface connectivity markers for the two subgroups functional and potato
performed the best.
converters (MCI-nc) based on 81 NC, 67 MCI-nc, 39
MCI-c, and 69 AD subjects from the ADNI database.
They investigated voxel based segmented tissue regions
for the whole brain in six different variants and for gray
matter (GM) and GM, white matter (WM), and cere-
brospinal fluid (CSF) combined, cortical thickness in
three different variants, and finally hippocampus volume
and shape in three different variants a total of ten differ-
ent methods. They conclude that all methods were able to
classify NC vs. AD with a sensitivity and specificity at the
range from 59% - 81% and 77% - 98%, respectively, which
is comparable to our classification. Other prediction stud-
ies have shown better classification rates at 67% - 92% for
cross-sectional studies [14,17,19,45,47] and 69% - 81,5%
for longitudinal studies [19-21]. The difference in the
classification accuracy between our method and the other
papers can be explained by the tuning of methods and the
use of different data sets.
Only our surface connectivity marker was able to clas-
sify MCI-c fromMCI-nc and not with a highly significant
result. This is in line with Cuignet et. al comparison study
for AD classification, where they found that only four
methods managed to predict MCI-c vs MCI-nc better
than a random classifier and none of those got signifi-
cantly better results [18]. The main reason for the low
result in the conversion case could be due to the fact that
MCI is a very in heterogeneous group that possibly could
convert rapidly to AD or be stable for many years before
conversion.
Other studies have investigated the change locally in
the hippocampus. Wang et al. [13] have used large-
deformation diffeomorphic high-dimensional brain map-
ping to quantify and compare changes in the hippocampal
shape as well as volume. They found that shape changes
were largely confined to the head of hippocampus and
subiculum for normal controls (NC). Other studies have
Lillemark et al. BMCMedical Imaging 2014, 14:21 Page 9 of 12
http://www.biomedcentral.com/1471-2342/14/21
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
a
1−specificity
se
n
si
tiv
ity
ROC for NC vs. AD 
Proc all
Proc func
Proc potato
Surf all
Surf func
Surf potato
Whole brain
Hippo
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1−specificity
se
n
si
tiv
ity
ROC for NC vs. MCI
Proc all
Proc func
Proc potato
Surf all
Surf func
Surf potato
Whole brain
Hippo
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1−specificity
se
n
si
tiv
ity
ROC for MCI vs. AD 
Proc all
Proc func
Proc potato
Surf all
Surf func
Surf potato
Whole brain
Hippo
b
c
Figure 3 (a) show the ROC for AD vs NC, (b) shows the ROC for NC vs. MCI, and (c) shows the ROC for MCI vs. AD.
confirmed these shape changes for the hippocampus
[14-16] based on shape models and local hippocampal
atrophy patterns. We have focused on investigating the
relationship between the different regions of the brain and
how they differ between healthy subjects and AD patients.
This way of investigating the regions could make it pos-
sible to incorporate different kind of knowledge into the
same model where one could go from the individual scale
of each region, to the interaction between the regions
and finally to combined picture of the brain as one whole
region.
Table 7 The AUC and corresponding p-values for the
classification of MCI-c andMCI-nc
Markers AUC p−value
HP/ICV 0.466 0.516
WB/ICV 0.512 0.823
Surface all 0.542 0.416
Surface func 0.624 0.017
Surface potato 0.603 0.048
Procrustes all 0.465 0.486
Procrustes func 0.498 0.964
Procrustes potato 0.534 0.501
Only the surface connectivity markers was able to significantly discriminate the
two groups; functional and potato-shaped.
An alternative use of MRI images for early prediction
of AD is by using texture analysis where different textures
features is used to construct a computational framework
which have been able to discriminate AD, MCI and NC
with a separability of up to 95% [23,40,48]. This indicates
that one can combine the three different kinds of mark-
ers; volume, texture and shape/proximity markers to get a
more sophisticated picture of the disease progression.
Other image modalities such as single-photon emis-
sion computed tomography (SPECT), functional MRI and
MR spectroscopy (MRS), positron emission tomography
(PET), and molecular imaging have been used for investi-
gation of brain changes related to AD. SPECT combined
with MRI images can give additional information about
disease progression when combined [49]. Functional MRI
and MR spectroscopy (MRS) have shown changes in
metabolic levels even prior to symptom onset in AD,
but are difficult to implement in clinical settings due to
technical support [50,51]. PET metabolic imaging with
radioactive glucose has also been used to examined the
functional change and tracking of the AD disease progres-
sion [52,53]. Due to the invasiveness, radiation dose limi-
tation, requiring lumbar punctures and high cost, PET is
unsuitable for repeated measurements of a single patient
or screening programs for large populations. Molecular
imaging with amyloid tracers have showed great potential
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as to be accurate markers for early diagnosis of AD, but do
not show progression in established disease [54,55], which
is our object of interest.
To conclude structural MRI is an suitable image modal-
ity for detection of AD and AD progression. Our mark-
ers have shown promising results in capturing how the
proximity of different regions in the brain can aid in
AD diagnosis and prognosis. The proximity analysis cap-
tures additional information about the whole brain com-
pared to atrophy scores. This additional information can
contribute to the refinement of the AD markers and
may be able to give a more detailed picture of AD
progression.
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